Genetic testing examines DNA, chromosomes, RNA, or related biological signals to answer a medical question. It may confirm an inherited disorder, estimate future disease risk, identify carrier status, guide medication choice, assess a pregnancy, screen a newborn, or analyze mutations in a tumor. The right test depends on why testing is being considered and which kinds of genetic changes could provide a useful answer.
Results are not always simple. A pathogenic variant may explain a diagnosis or indicate increased risk, but it may not predict exactly when symptoms will begin or how severe they will be. A negative result can be reassuring while still leaving residual risk. A variant of uncertain significance is not a confirmed disease finding. Before testing, patients should understand the test’s purpose, scope, possible results, family implications, privacy issues, and likely next steps. Clinical interpretation works best when the laboratory result is combined with personal history, family history, examination findings, and other medical evidence.
- Genetic tests can diagnose disease, estimate risk, identify carriers, guide medications, evaluate pregnancies, screen newborns, or profile tumors.
- The most informative test matches the clinical question and the variant types expected for the condition.
- A positive result may confirm a diagnosis or risk, but penetrance and severity can vary.
- A negative result means no reportable finding was detected within the test’s limits, not that all genetic causes are excluded.
- A variant of uncertain significance generally should not drive major medical decisions by itself.
- Results may affect biological relatives, so consent and post-test counseling are important.
Table of Contents
- What Genetic Testing Examines
- Main Types of Genetic Tests
- Medical Reasons for Testing
- How Testing Is Done
- What Positive, Negative, and Uncertain Results Mean
- Benefits and Clinical Value
- Risks, Limitations, and Privacy
- Choosing a Test and Planning Follow-Up
What Genetic Testing Examines
Genetic testing looks for biological differences that may influence health. Most tests analyze DNA, the molecule that contains genes and other regulatory information. Some examine whole chromosomes, RNA made from genes, proteins, enzymes, or metabolites that reveal how a genetic pathway is functioning.
A DNA change is called a variant. Human genomes contain millions of variants, and most are harmless. Clinical testing filters this ordinary variation to identify changes that may cause disease, increase susceptibility, alter medication response, or explain a tumor’s behavior.
Tests can examine different scales:
- A single known position in one gene.
- All coding regions of one gene.
- Several genes on a panel.
- Large deletions or duplications across chromosomes.
- The protein-coding exome.
- Nearly the entire genome.
- Mitochondrial DNA.
- Repeated DNA sequences, methylation patterns, or structural rearrangements.
The sample and purpose also matter. Germline testing usually uses blood or saliva and looks for variants present from conception that may be inherited. Somatic testing examines acquired changes in a tumor or another affected tissue. Prenatal testing evaluates a pregnancy. Newborn screening searches for conditions where early treatment can prevent harm.
“Genetic test” is therefore an umbrella term rather than one procedure. A DNA test for a known family variant is fundamentally different from a chromosome microarray, a pharmacogenetic panel, or tumor sequencing. The test order should name the clinical question, not merely request “genetic testing.”
Three standards help determine whether a test is medically useful:
- Analytical validity: how accurately the laboratory detects the genetic change.
- Clinical validity: how reliably the detected change relates to a condition or outcome.
- Clinical utility: whether the result can improve decisions, care, or outcomes.
A test can be analytically excellent yet clinically unhelpful if the gene-disease link is weak or no useful action follows the result.
Main Types of Genetic Tests
Different methods answer different questions. Some overlap, but no single test detects every genetic mechanism.
Targeted and single-gene tests
Targeted testing looks for one known variant or a small group of variants. It is often used after a pathogenic variant has been found in a relative. This approach is fast and highly interpretable but will not identify other changes outside the target.
A single-gene genetic test analyzes one gene when the clinical picture strongly points to a specific disorder. The assay may include sequencing plus deletion and duplication analysis. Specialized methods may still be needed for repeat expansions, methylation, or complex structural changes.
Multigene panels
A panel examines several genes associated with a shared condition or symptom group. Panels are common for hereditary cancer, cardiomyopathy, epilepsy, hearing loss, immune disorders, and many rare diseases. They can be efficient when multiple genes produce overlapping features, though larger panels increase the chance of uncertain findings. The detailed genetic panel test guide explains these tradeoffs.
Chromosome tests
A karyotype views chromosome number and large structural changes. It can detect extra or missing chromosomes and some translocations or inversions. Chromosomal microarray looks for smaller deletions and duplications, called copy-number variants, across the genome. Neither method replaces sequencing for small DNA changes.
Exome and genome sequencing
Exome sequencing focuses mainly on protein-coding regions, which represent a small fraction of the genome but contain many known disease-causing variants. Genome sequencing analyzes coding and noncoding DNA more broadly and can detect some structural variants better, although interpretation of many noncoding findings remains limited.
These tests are useful for complex or unexplained disorders, particularly after focused testing is negative. Trio testing of a child and both biological parents can improve interpretation. A whole-exome sequencing test or whole-genome sequencing test may also identify secondary findings unrelated to the original question.
Biochemical and functional genetic tests
Some inherited disorders are detected by measuring enzyme activity, metabolites, proteins, or gene expression. Newborn screening often begins with biochemical markers rather than DNA sequencing. RNA studies can show whether a DNA variant disrupts splicing. These tests may confirm the functional effect of a genetic change.
Pharmacogenetic testing
Pharmacogenetic tests analyze variants that affect drug metabolism, transport, targets, or immune reactions. The result may help select a medication or dose, but it is only one part of prescribing. Age, kidney and liver function, interacting drugs, diagnosis, and treatment goals remain important. The pharmacogenetic testing guide covers this use in more detail.
Tumor and liquid-biopsy testing
Tumor genomic testing searches for acquired mutations, fusions, amplifications, or other biomarkers that may guide cancer diagnosis or therapy. A blood-based liquid biopsy analyzes tumor-derived material in circulation. Tumor findings are not automatically inherited, although some can suggest the need for separate germline testing.
Medical Reasons for Testing
The same laboratory method can be used for different clinical purposes, and the meaning of a result changes with the purpose.
| Purpose | Who is tested | Main question |
|---|---|---|
| Diagnostic | Person with symptoms or abnormal findings | Does a genetic cause explain the condition? |
| Predictive or presymptomatic | Person without current symptoms | Was a disease-associated variant inherited? |
| Carrier | Person planning pregnancy or with family risk | Could a recessive or X-linked condition be passed on? |
| Prenatal | Pregnancy | Is a fetal genetic or chromosome condition present or more likely? |
| Newborn screening | Baby shortly after birth | Is urgent follow-up needed for a treatable condition? |
| Pharmacogenetic | Person starting or using medication | Could inherited variation affect response or toxicity? |
| Somatic or tumor | Person with cancer or another acquired disorder | Which mutations characterize the affected tissue? |
Diagnostic testing may end a long search, distinguish similar conditions, or provide access to disease-specific treatment. Predictive testing may identify future risk before symptoms develop, but it requires careful counseling because a result can affect life planning and family relationships.
Presymptomatic testing refers to a variant that predicts disease with high certainty if a person lives long enough, as in many Huntington disease cases. Predictive testing may indicate increased risk without certainty, as with some hereditary cancer or cardiomyopathy variants. The two terms are sometimes used loosely, so the report should describe penetrance and age-related risk rather than rely on a label.
Carrier testing concerns reproductive probability, not a general health score. Prenatal screening estimates risk, while prenatal diagnostic testing analyzes fetal or placental cells more directly. Newborn screening is a public-health process that requires rapid confirmation after an abnormal result.
Testing may also be used to clarify prognosis, determine eligibility for a therapy, find relatives who need surveillance, or support reproductive options. A test should be ordered because the result can answer a defined question, not simply because sequencing is available.
How Testing Is Done
The process usually begins before the sample is collected. A clinician reviews the person’s symptoms, medical records, family history, ancestry when relevant, previous tests, and the likely inheritance pattern. This information determines which genes and variant types need to be assessed.
Before the test
Informed consent should cover:
- The purpose and scope of testing.
- Possible positive, negative, uncertain, carrier, and secondary results.
- Technical and interpretive limitations.
- Whether results may affect relatives.
- Options for receiving or declining secondary findings.
- How samples and data will be stored or shared.
- Cost, insurance coverage, and possible out-of-pocket charges.
- The plan for confirmation, follow-up, and reanalysis.
Some tests require detailed genetic counseling, while others can be ordered with focused education. The complexity of consent should match the potential consequences.
Sample collection
Blood and saliva are common. Cheek swabs, skin biopsies, muscle, amniotic fluid, chorionic villi, tumor tissue, bone marrow, or other samples may be needed. No fasting is required for most DNA tests, but recent transfusion, bone-marrow transplant, active blood cancer, and sample contamination can affect results.
Laboratory analysis
The laboratory extracts DNA or other material, performs the validated assay, checks quality, and uses bioinformatics to identify findings. Specialists then classify variants and interpret them in the clinical context. Some findings are confirmed with a second method or sample.
Turnaround time ranges from days for urgent targeted testing to weeks or months for broad or specialized analyses. The report should state what was tested, the method, important coverage gaps, findings, classification, interpretation, and recommendations.
Results visit
Patients should receive the full report and an explanation of what it changes. A result is most useful when translated into specific next steps, such as surveillance, treatment, family testing, reproductive counseling, or further diagnostic work.
What Positive, Negative, and Uncertain Results Mean
Genetic reports use categories that describe evidence, not personal destiny.
Positive result
A positive result usually identifies a pathogenic or likely pathogenic variant relevant to the test’s purpose. In diagnostic testing, it may confirm or strongly support a condition. In predictive testing, it may establish increased future risk. In carrier testing, it may show reproductive risk. In tumor testing, it may identify a treatment biomarker.
The finding still requires clinical correlation. Penetrance may be incomplete, age of onset may vary, and the same variant can produce different severity in different relatives. Some positive results identify susceptibility rather than certainty.
Negative result
A negative result means no clinically significant finding was detected within the test’s scope. It is highly informative when a known family variant was specifically excluded. It is less definitive when no familial cause is known or when the suspected disorder has many genetic mechanisms.
Reasons for an uninformative negative result include untested genes, poor coverage, deep intronic variants, repeat expansions, structural changes, mosaicism, unknown gene-disease relationships, or a nongenetic cause. Medical follow-up may still be based on symptoms and family history.
Variant of uncertain significance
A VUS has insufficient or conflicting evidence. It is not a confirmed cause and generally should not direct irreversible treatment, surgery, or predictive testing in healthy relatives. Selected family studies or functional testing may help, and the classification may change over time. The VUS result guide explains how to manage this uncertainty.
Benign and likely benign variants
These variants are considered unlikely to cause the tested disorder. Laboratories often omit them from the main report because everyone carries many harmless differences.
Secondary and incidental findings
Broad sequencing may identify a pathogenic variant unrelated to the original reason for testing. Consent should address whether such findings will be analyzed and returned. An actionable secondary finding may lead to prevention or surveillance but should be confirmed and interpreted separately.
| Category | Can it guide care? | Typical next step |
|---|---|---|
| Pathogenic or likely pathogenic | Often, when clinically relevant | Diagnosis-specific care and family assessment |
| No significant finding | Sometimes, depending on residual risk | Review limits and consider other testing if needed |
| VUS | Usually not by itself | Clinical management based on other evidence and possible reanalysis |
| Benign or likely benign | No disease-specific action | No action based on the variant |
Benefits and Clinical Value
Genetic testing can replace uncertainty with a molecular explanation. A diagnosis may stop repeated investigations, connect a person with specialists and support groups, clarify prognosis, and identify condition-specific treatment.
Other benefits include:
- Starting surveillance before symptoms or complications appear.
- Avoiding procedures that are unlikely to help.
- Choosing medication or dose more safely in selected settings.
- Identifying relatives who can receive targeted testing.
- Clarifying reproductive risk and available options.
- Providing an explanation for a child’s developmental or congenital findings.
- Distinguishing inherited from acquired tumor changes.
- Supporting eligibility for clinical trials or targeted therapy.
A negative result can also help. If a person tests negative for a known familial pathogenic variant, enhanced surveillance related only to that variant may no longer be necessary. A negative prenatal diagnostic test may reduce uncertainty. An uninformative result can still narrow the differential diagnosis or show which mechanisms were assessed.
Clinical value depends on actionability. Finding a variant is not useful merely because it is technically detectable. The result should change diagnosis, prevention, treatment, prognosis, reproductive understanding, or another meaningful aspect of care.
Benefits may extend to relatives, but the tested person retains control over disclosure except in limited situations governed by local law and professional ethics. Genetics teams can help communicate a confirmed family finding without sharing unnecessary private medical details.
Risks, Limitations, and Privacy
The physical risk of a blood draw or saliva collection is small, but the informational consequences can be substantial.
Emotional and family effects
Results may cause anxiety, grief, survivor guilt, changed self-image, or conflict over whether relatives want to know. A variant can reveal unexpected biological relationships or raise questions about children and future pregnancies.
Uncertainty and misinterpretation
A VUS may be mistaken for a diagnosis. A negative result may be treated as proof that no inherited risk exists. A moderate-risk variant may be presented as certainty. These errors can lead to unnecessary procedures or missed surveillance.
Technical limitations
Sequencing may not reliably detect every deletion, duplication, repeat expansion, structural rearrangement, methylation change, low-level mosaic variant, or hard-to-read region. A report should state the method and limitations. Some conditions require a combination of DNA, chromosome, biochemical, and functional tests.
Knowledge limitations
Variant interpretation reflects current evidence. Databases underrepresent many ancestry groups, increasing uncertain results and reducing the accuracy of some risk estimates. Gene-disease relationships can be revised. Reanalysis may produce a different interpretation later.
Privacy and discrimination
Genetic information is identifying and shared across families. Protections against discrimination differ by country and may not apply equally to health insurance, life insurance, disability coverage, long-term-care insurance, employment, education, or military service. Patients should review local law and the test provider’s data policies.
Direct-to-consumer services may store samples, allow research use, or provide raw data with uncertain clinical quality. Health findings from consumer testing should generally be confirmed in a clinical laboratory before medical action. Deleting an online account may not remove data already shared under previous consent.
Cost and access
Testing can generate follow-up costs for counseling, confirmation, imaging, procedures, or relatives. Insurance coverage may require prior authorization or clinical criteria. Unequal access to specialists and preventive care can reduce the benefit of finding risk.
Choosing a Test and Planning Follow-Up
The best test is the narrowest or broadest method that can reliably answer the clinical question without creating unnecessary ambiguity. Test selection should consider the suspected diagnosis, expected variant types, family history, urgency, cost, and what will happen with each possible result.
Before testing, ask:
- What question is this test intended to answer?
- Is this a screening or diagnostic test?
- Which genes, chromosomes, or variant types are included?
- What important changes can the method miss?
- How common are uncertain results?
- Will secondary or carrier findings be reported?
- Would testing an affected relative first be more informative?
- How will a positive, negative, or uncertain result change care?
- Who will explain the report?
- Can the data be reanalyzed later?
After testing, keep the complete report. Record the laboratory, test name, date, genes or regions assessed, exact variant notation, and classification. These details allow relatives to receive accurate targeted testing and help future clinicians understand what was already done.
A positive result should lead to a condition-specific management plan. A negative result should prompt a residual-risk discussion rather than an automatic stop. A VUS should be tracked without being overused. If the result does not explain the clinical picture, options may include a complementary method, broader sequencing, testing another tissue, family studies, or research enrollment.
Variant reevaluation and data reanalysis are not the same. Reevaluation reviews the evidence for a previously reported variant. Reanalysis returns to a broader dataset and may search newly recognized genes or findings. Policies vary, so patients should ask whether the laboratory or ordering clinician initiates review and how updated contact information will be maintained.
Genetic counseling is particularly useful for predictive testing, hereditary cancer or cardiac risk, prenatal decisions, broad sequencing, adult-onset findings, and complex family implications. A good testing process does more than produce a laboratory result; it connects that result to care that is proportionate, evidence-based, and understandable.
References
- Genetic Testing 2024
- Characterizing trends in clinical genetic testing 2025
- Points to consider in the reevaluation and reanalysis of genomic test results: A statement of the American College of Medical Genetics and Genomics (ACMG): Addendum 2024 (Position Statement)
- Defining the Critical Components of Informed Consent for Genetic Testing 2021
- Recommendations for reporting results of diagnostic genomic testing 2022 (Guideline)
- What are the different types of genetic tests? 2021
Disclaimer
Genetic testing should be selected and interpreted using personal medical information, family history, and the test’s technical scope. Do not change treatment, surveillance, medication, or reproductive plans based only on a laboratory label or consumer report. Discuss clinically important results with the ordering clinician or a qualified genetics professional.
